君實生物任命Patricia Keegan博士為首席醫學官
格隆匯APP獲悉，北京時間2020年8月10日，君實生物(01877.HK/688180.SH)宣佈任命Patricia Keegan博士為首席醫學官(CMO)，負責公司臨牀開發項目的領導和管理。
Keegan博士在腫瘤治療，臨牀研究和藥政監管等方面擁有超過30年的經驗。在加入君實生物之前，Keegan博士在美國食品藥品監督管理局(FDA)工作30年，歷任腫瘤產品部醫學審評官、臨牀試驗設計和分析部副部長、腫瘤產品部部長，她在FDA的最後任職是腫瘤卓越中心(Oncology Center for Excellence，OCE)副主任。在加入FDA之前，Keegan博士在北卡羅萊納大學教堂山分校(University of North Carolina at Chapel Hill)擔任腫瘤科醫師和臨牀助理教授。
加入君實生物之後，Keegan博士將作為君實生物的首席醫學官領導和管理公司的臨牀開發項目，負責臨牀開發計劃的策略、方向和執行，並參與公司整體層面的戰略制定。
“我們非常歡迎Keegan博士的到來，”君實生物首席執行官李寧博士表示。“在過去30年間，Keegan博士作為一位經驗豐富的臨牀醫生和藥政監管人士，在腫瘤藥物的推進和審評審批等領域取得了驕人的業績和成果。我們期待在Keegan博士的助力下，君實生物的產品管線將得到不斷拓展，在全球範圍內加速進入商業化階段，並推動公司向‘立足本土，佈局全球’的戰略目標邁進。”
格隆匯APP瞭解到，Keegan博士在洛約拉大學斯特里奇醫學院(Loyola University Stritch School of Medicine)獲得醫學博士學位並完成內科住院醫師培訓，在洛斯維•帕克紀念研究所(Roswell Park Memorial Institute)完成腫瘤專科博士後培訓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
